Harald H. H. W. Schmidt

ORCID iD
https://orcid.org/0000-0003-0419-5549
  • Also known as
  • Show details Hide details
3H

Sources:
Harald H. H. W. Schmidt (2015-01-20)

  • Country
  • Show details Hide details
Germany

Sources:
Harald H. H. W. Schmidt (2016-01-24)

  • Keywords
  • Show details Hide details
nitric oxide,

Sources:
Harald H. H. W. Schmidt (2015-01-20)

cGMP,

Sources:
Harald H. H. W. Schmidt (2015-01-20)

pharmacology,

Sources:
Harald H. H. W. Schmidt (2015-01-20)

drug discovery,

Sources:
Harald H. H. W. Schmidt (2015-01-20)

ROS,

Sources:
Harald H. H. W. Schmidt (2015-01-20)

NADPH oxidase,

Sources:
Harald H. H. W. Schmidt (2015-01-20)

NOX,

Sources:
Harald H. H. W. Schmidt (2015-01-20)

soluble guanylate cyclase,

Sources:
Harald H. H. W. Schmidt (2015-01-20)

VASP,

Sources:
Harald H. H. W. Schmidt (2015-01-20)

sGC,

Sources:
Harald H. H. W. Schmidt (2015-01-20)

NOS

Sources:
Harald H. H. W. Schmidt (2015-01-20)

  • Other IDs
  • Show details Hide details
ResearcherID: B-1549-2008

Sources:
ResearcherID (2013-07-04)

Scopus Author ID: 7404731233

Sources:
Scopus - Elsevier (2014-03-27)

Biography

Harald Schmidt is Professor of Pharmacology & Personalised Medicine at the Cardiovascular Research Institute Maastricht, co-leader of Maastricht University’s Faculty of Health, Medicine and Life Sciences innovation platform, and Board Member of the Maastricht Institute of Advanced Studies at Maastricht University, Netherlands. He leads a research program as European Research Council Advanced Investigator, a EUROSTAR programme, and founded a European Science Foundation COST Action. Before he had worked in Australia, Germany and USA in different academic and business leadership positions. These include chair of Monash University’s Centre for Vascular Health, Australia, different chairs in pharmacology and director of a drug discovery CRO at TransMIT, Giessen, Germany. He also co-founded and for two years led as CEO Vasopharm GmbH, a drug discovery company now entering into phase III clinical development. His research focuses on cardiovascular and neurological disease mechanisms, target validation, drug and biomarker discovery, personalised and network medicine. Professor Schmidt has published over 160 peer-reviewed papers, reviews, books and patents (Hirsch-index of 65; Google-Scholar: tinyurl.com/q4july7). He is a member of the European Society of Cardiology Working Group - Cardiovascular Pharmacology and Drug Therapy, Section Editor of the Public Library of Science, and Member of the Faculty of 1000 Medicine. He has been awarded the Roche Molecular Biochemicals Research Prize for Cell Biology, the Phoenix Research Prize in Pharmacy, and the Pro Scientia Prize.

Record last modified {{lastModifiedDate}}